ReGenX Biosciences

A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.

Launch date

2009

Employees

Market cap

Enterprise valuation

€391m (Public information from Sep 2024)

Rockville Maryland (HQ)

http://regenxbio.com

https://twitter.com/regenxbio http://www.facebook.com/pages/REGENX-Biosciences-LLC/89894384909 https://www.linkedin.com/company/regenx

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	155m	470m	113m	90.2m	92.2m	282m	233m
% growth	339 %	204 %	(76 %)	(20 %)	2 %	206 %	(17 %)
EBITDA	(115m)	161m	(263m)	(251m)	(200m)	(5.7m)	(153m)
% EBITDA margin	(74 %)	34 %	(233 %)	(278 %)	(217 %)	(2 %)	(66 %)
Profit	(111m)	128m	(280m)	(263m)	(226m)	(85.7m)	(133m)
% profit margin	(72 %)	27 %	(249 %)	(292 %)	(245 %)	(30 %)	(57 %)
EV / revenue	7.9x	2.0x	5.5x	5.7x	5.0x	1.6x	2.0x
EV / EBITDA	-10.6x	5.9x	-2.4x	-2.0x	-2.3x	-78.3x	-3.1x
R&D budget	166m	181m	242m	232m	-	-	-
R&D % of revenue	108 %	39 %	215 %	257 %	-	-	-

Date	Investors	Amount	Round
-	Eight Roads Ventures	N/A	-
May 2011	National Institutes of Health Fondazione Telethon	$2.8m	Grant
Mar 2013	National Institutes of Health Fondazione Telethon	$7.7m	Grant
Nov 2013	N/A	$7.9m	Early VC
Jan 2015	Venrock Brookside Capital	$30.0m	Series C
May 2015	Venrock QVT Financial LP Foresite Capital Janus Capital Group Jennison Associates Sectoral Asset Management F-Prime Vivo Capital Perceptive Advisors	$70.5m	Series D
Sep 2015	N/A	N/A	IPO
Mar 2017	N/A	$87.2m	Post IPO Equity
Aug 2018*	N/A	$202m	Post IPO Equity
Jan 2020	Frazier Healthcare Partners	N/A	Post IPO Equity
Jan 2021*	N/A	$230m	Post IPO Equity
Mar 2024*	N/A	$140m	Post IPO Equity
Total Funding		€108m

Tech stackLearn more about the technologies and tools that this company uses.